Mammary Cell News Volume 8.25 | Jun 30 2016

TOP STORY

Breast Cancer Cells Use Newfound Pathway to Survive Low Oxygen Levels in Tumors

Researchers have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors. [Press release from NYU Langone Medical Center discussing online prepublication in Nature Cell Biology] Press Release | Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

p62/SQSTM1 Enhances Breast Cancer Stem-Like Properties by Stabilizing MYC mRNA

Investigators found that p62 expression was elevated in breast cancer stem cells (BCSCs), including CD44⁺CD24⁻ fractions, mammospheres, ALDH1⁺ populations and side population cells. [Oncogene] Full Article

PTPRO Represses ERBB2-Driven Breast Oncogenesis by Dephosphorylation and Endosomal Internalization of ERBB2

Scientists revealed the deletion of Ptpro in MMTV-Erbb2 transgenic mice dramatically shortened the mammary tumor latency and accelerated tumor growth due to loss of Ptpro within breast cancer cells but not in surrounding tissue as confirmed by hetero-transplantation studies. [Oncogene] Full Article

COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis

Investigators revealed that COX-2 induces cancer stem-like cells (SLCs) by EP4-mediated NOTCH/WNT signaling. Ectopic COX-2 over-expression in MCF-7 and SKBR-3 cell lines resulted in: increased migration/invasion/proliferation, epithelial-mesenchymal transition, elevated SLCs (spheroid formation), increased ALDH activity and colocalization of COX-2 and SLC markers in spheroids. [Stem Cells] Abstract

Myosin 1e Promotes Breast Cancer Malignancy by Enhancing Tumor Cell Proliferation and Stimulating Tumor Cell De-Differentiation

Researchers suggest that Myosin 1e (MYO1E) contributes to breast tumor malignancy and regulates the differentiation and proliferation state of breast tumor cells. [Oncotarget] Full Article

3,6-Dihydroxyflavone Suppresses the Epithelial-Mesenchymal Transition in Breast Cancer Cells by Inhibiting the Notch Signaling Pathway

Scientists found that 3,6-DHF could effectively inhibit epithelial to mesenchymal transition (EMT) in BC cells in vitro and in vivo. 3,6-DHF effectively inhibits the formation and proliferation of BCSCs, and consequently reduces the tumor-initiating capacity of tumor cells in NOD/SCID mice. [Sci Rep] Full Article

AurkA Controls Self-Renewal of Breast Cancer-Initiating Cells Promoting wnt3a Stabilization through Suppression of miR-128

Researchers discovered that AurkA knock-down reduced wnt3a mRNA and suppressed metastatic signature of MDA-MB-231 cells. As a consequence, the amount of BCICs and their migratory capability dramatically decreased. [Sci Rep] Full Article

γ-Tocotrienol Reversal of Epithelial-to-Mesenchymal Transition in Human Breast Cancer Cells Is Associated with Inhibition of Canonical Wnt Signaling

γ-Tocotrienol was found to induce dose-responsive inhibition of MDA-MB-231 and T-47D cell growth at doses that had no effect on immortalized normal MCF-10A mammary epithelial cells. These growth inhibitory effects were associated with suppression in canonical Wnt signalling, reversal of epithelial-to-mesenchymal transition (EMT) and significant reduction in breast cancer cell motility. [Cell Prolif] Abstract

CLINICAL RESEARCH

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer

Scientists evaluated the efficacy of three first-line chemotherapy combination regimens for HER2-negative metastatic breast cancer. [Clinical Breast Cancer] Abstract

Angiotensin II-Receptor Inhibition with Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients with Early Breast Cancer: A Randomized Clinical Trial

Investigators evaluated whether angiotensin II antagonist treatment with candesartan can prevent or ameliorate trastuzumab-related cardiotoxic effects. [JAMA Oncol] Abstract

CDK4/6 Inhibitors for the Treatment of Advanced Hormone Receptor Positive Breast Cancer and Beyond: 2016 Update

The author reviews the preclinical and clinical development of the compounds (palbociclib, ribociclib and abemaciclib) as well as discussing the role for novel applications of these agents outside the arena of HR (hormone receptor)-positive, human epidermal growth factor receptor-negative advanced breast cancer. [Expert Opin Pharmacother] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Human and AI System Partnership Achieves Nearly Perfect Accuracy in Breast Cancer Detection

Harvard-based artificial intelligence system won the Camelyon16 challenge, a competition comprised of participants introducing their individual AI systems and its ability to facilitate automated lymph node metastasis diagnosis. [Press release from Ampronix discussing research presented at the 2016 International Symposium on Biomedical Imaging (ISBI), Prague] Press Release

Cancer Drug Designed at Bath Shows Continuing Clinical Impact

New clinical data was revealed for Irosustat, a drug pioneered at the University of Bath that could prolong the lives of women with breast cancer. [Press release from University of Bath discussing research presented at the American Society for Clinical Oncology (ASCO), Chicago] Press Release

Researcher Awarded $2.8 Million to Study Use of Nanotechnology in Cancer Treatment

Julia Ljubimova, MD, PhD, director of the Nanomedicine Research Center in the Cedars-Sinai Department of Neurosurgery, has received a $2.8 million federal grant to advance her research of tumor nanoimmunology to treat cancers of the brain, breast, lung and other organs. [Cedars-Sinai] Press Release

Galena Biopharma Discontinues NeuVax™ Phase III, PRESENT Interim Analysis Based on Independent Data Monitoring Committee Recommendation

Galena Biopharma announced the recommendation from the Independent Data Monitoring Committee on the interim analysis for Galena’s NeuVax™ Phase III PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial. [Galena Biopharma, Inc.] Press Release

Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of Advanced HER2⁺ Metastatic Breast Cancer

Cascadian Therapeutics announced that the ONT-380 program in advanced HER2⁺ metastatic breast cancer has received Fast Track designation from the U.S. Food and Drug Administration (FDA). [Cascadian Therapeutics] Press Release

NEW Gordon Research Conference – Tissue Niches & Resident Stem Cells in Adult Epithelia
August 7-12, 2016
Hong Kong, China

Visit our events page to see a complete list of events in the mammary cell community.

NEW Postdoctoral Fellow – Breast Cancer Biology (Icahn School of Medicine at Mount Sinai)

NEW Postdoctoral Researcher – Basic & Translational Breast Cancer Research (Northwestern Universtiy)

Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

Postdoctoral Associate – Premalignant Progression to Invasive Breast Cancer (Tulane Medical School)

Postdoctoral Fellow – Molecular Genetics of Breast Cancer (German Cancer Research Centre)

Postdoctoral Researcher – Aheransotic Agents against Intracellular Cancer Targets (University of Oxford)

Postdoctoral Fellowship – Cancer Research (German Cancer Research Center)

Postdoctoral Fellow – Proteogenomic Bioinformatics of Breast Cancer (Lund University)

Postdoctoral Fellow – Cancer Biology (Hamad bin Khalifa University)

PhD Fellow – Small X-Ray Angle for Breast Cancer Diagnosis (CEA Tech)

Postdoctoral Fellow(s) – Various Projects (National University of Singapore)

Research Associate – Various Medical Disciplines (Jinan University)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.